Alzheimer Disease Clinical Trial
Official title:
Effect of Deep Transcranial Magnetic Stimulation (dTMS) on Cognition in Older Adults With Subjective Cognitive Decline (SCD)
Deep transcranial magnetic stimulation (dTMS) is a brain stimulation technique that involves generating a brief magnetic field in a coil that is placed on the scalp. The magnetic field passes through the skull and induces a weak electrical current in the brain that briefly activates neural circuits at the stimulation site. The Brainsway dTMS H7-Coil is able to target an area of the brain that has been shown in studies to be linked to greater resilience to cognitive decline. In this study, the investigators will combine dTMS with cognitive training in older adults with subjective cognitive decline (SCD) and examine the effect of this treatment on memory, other cognitive abilities, and mood. In addition, the investigators will examine the combined effects of dTMS and cognitive training on brain activity as measured using electroencephalography (EEG). Approximately 30 older adults from ages 55 to 70 with SCD and a positive family history of Alzheimer's disease will be enrolled in this study.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | November 15, 2024 |
Est. primary completion date | October 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 70 Years |
Eligibility | Inclusion Criteria: - have a family history of late onset sporadic Alzheimer's disease (AD) as defined by having a first degree relative, living or deceased, with a probable or confirmed diagnosis of AD - have subjective memory decline and concern about memory changes - score 26 or higher on the Montreal Cognitive Assessment (MoCA) - are willing to provide informed consent - are able to follow the treatment schedule - are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications) - have a satisfactory safety screening questionnaire for TMS - have an informant/study partner who is able to complete study questionnaires regarding the participant Exclusion Criteria: - have a metal plate in their head, except in the mouth (such as an ear implant, implanted brain stimulators, aneurysm clips) - have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures - have a cardiac pacemaker - have an implanted medication pump - have a central venous line - have a significant heart condition - have current depression or a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia other than AD - have a history of substance abuse in the last 6 months - have a history of stroke or other brain lesions - have a personal history of epilepsy - have a family history of epilepsy - are a pregnant or breast-feeding woman - have a history of abnormal MRI of the brain - have significant hearing loss requiring use of hearing aids - have untreated hypo- or hyper-thyroidism - have TMS contraindications - have unstable medical condition(s) - regularly use benzodiazepines or other hypnotics within 2 weeks of randomization |
Country | Name | City | State |
---|---|---|---|
Canada | Rotman Research Institute at Baycrest | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Rotman Research Institute at Baycrest | Brainsway, Centre for Addiction and Mental Health |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of scheduled treatment sessions that are attended by study participants | There are in total 20 sessions of dTMS intervention and 20 sessions of sham stimulation. | 19 weeks | |
Secondary | Change in baseline memory performance on a neuropsychological battery | Memory score from the neuropsychological battery at baseline will be compared to 4 weeks of intervention and at 1-month follow-up. | 19 weeks | |
Secondary | Change in executive function performance on a neuropsychological battery | Executive function scores from the neuropsychological battery at baseline will be compared to 4 weeks of intervention and at 1-month follow-up. | 19 weeks | |
Secondary | Change in baseline in scores on the Geriatric Depression Scale (GDS). | GDS is a 15-item self-report scale that measures an elderly individual's mood. A score greater than 5 suggests that the individual may be depressed. Administration time is approximately 5 minutes.
The scores at baseline will be compared to 4 weeks of intervention and at 1-month follow-up. |
19 weeks | |
Secondary | Change in baseline in scores on the Geriatric Anxiety Inventory (GAI). | The GAI is a 20-item self-report measure of anxiety developed for older adults. Administration time is approximately 5 minutes.
The scores at baseline will be compared to 4 weeks of intervention and at 1-month follow-up. |
19 weeks | |
Secondary | Change in baseline in scores on the Neuropsychiatric Inventory Questionnaire (NPI-Q) | The NPI assesses dementia-related behavioural symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity, night-time behavioural disturbances and appetite and eating abnormalities. Administration time is approximately 15 minutes.
The scores at baseline will be compared to 4 weeks of intervention and at 1-month follow-up. |
19 weeks | |
Secondary | Change in slow wave and resting state activity | Measured with electroencephalography (EEG) following 4 weeks of intervention and at 1-month follow-up. | 17 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |